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Abstract
 .Incubation of cultured bovine vascular smooth muscle cells VSMC with forskolin increased cAMP as measured by an
 .  .increase in cAMP-dependent protein kinase PKA activation PKA ratio . Forskolin also produced a concentration- and
 . time-dependent increase in activity 3–5-fold within 15 min of a PDE4 cAMP-specific cyclic nucleotide phosphodi-
.esterase . The increase in PDE4 activity was not affected by cycloheximide and thus not likely due to increased synthesis of
the enzyme. Activation, which was preserved during partial purification of the enzyme by chromatography on Sephacryl
S-200 and MonoQ, was most likely due to a covalent modification. Incubation of cell homogenates with the catalytic
 .subunit of PKA PKA induced a ;5-fold activation of PDE4 with a time course similar to that in intact cells afterc
forskolin addition. The forskolin-mediated activation was reversed during incubation of homogenates at room temperature
for two hours. Addition of PKA resulted in rapid reactivation of PDE4. These data are consistent with the hypothesis thatc
rapid, reversible activation of PDE4 in cultured VSMC is mediated by PKA.
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1. Introduction
Intracellular concentrations of cAMP are regulated
both by alteration of rates of synthesis by adenylyl
cyclases and of degradation by cyclic nucleotide
 .phosphodiesterases PDEs . Seven PDE families,
w xPDE1-7, have been identified and characterized 1–7 .
PDE4 isoenzymes have a high affinity for cAMP
and are relatively sensitive to inhibition by rolipram
and Ro-20-1724. PDE4s are products of at least four
w xdistinct genes in humans and rats 8,9 . The corre-
sponding isoenzymes, named PDE4A-D, are ex-
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pressed in many tissues, but in different amounts and
proportions. Whereas PDE4C and PDE4D mRNAs
have not been detected in peripheral blood cells or
lymphocyte-derived cell lines, respectively, PDE4A
w xand PDE4B mRNAs are found in most tissues 10 .
Different PDE4s can be generated from the same
gene, as is the case for one PDE4 gene the so called
.‘ratPDE3rIVd’ from which three PDE4 mRNAs
can be produced in brain, Sertoli cells and FRTL-5
cells, a thyroid-derived cell line. Of PDE4 isoforms
synthesized from these mRNAs, one was phosphory-
lated and activated by PKA in vitro, whereas the two
w xothers were constitutively active 11 . Rapid activa-
tion of PDE4 in FRTL-5 cells via cAMP-dependent
w xphosphorylation was recently reported 12 .
 .In vascular smooth muscle VSM , representatives
of at least four of the seven cyclic nucleotide PDE
families are present: PDE1, PDE3, PDE4 and PDE5
w x13 . Specific PDE inhibitors, effective in intact cells,
have been used to evaluate the role of different PDEs
in regulation of VSM relaxation, which is promoted
w xby agents that increase cAMP 14 . Although both
PDE3 and PDE4 are present in VSM and specific
PDE3 inhibitors are potent vasodilators, PDE4 in-
w xhibitors alone produce little or no relaxation 15 .
PDE4 inhibitors do, however, potentiate effects of
w xPDE3 inhibitors 13 . Inhibitors of PDE3, but not
w xPDE4, relax rat aorta denuded of endothelium 13 . In
rat aorta preparations with intact endothelium, the
effects of PDE4 inhibitors are enhanced by PDE3
inhibitors or by nitrovasodilators and other agents
that increase cGMP; they are blocked by the nitric
 .oxide synthase NOS inhibitor L-N-methyl-arginine
w x13 . These results suggest that in these VSM prepara-
tions when PDE3 is inhibited by PDE3 inhibitors or
endogenously produced cGMP, increased cAMP is
hydrolyzed primarily by PDE4. In rat aortic smooth
muscle, stimulation of guanylyl cyclase also results in
increased cAMP, probably via cGMP-inhibition of
w xPDE3 16 . In spite of the effect of rolipram on intact
vessels in vitro, no obvious cardiovascular effects of
rolipram in healthy human volunteers and patients
w xwere found 17 . Inhibition of PDE4, as well as of
PDE3, had a pronounced relaxing effect in bronchial
smooth muscle in vitro. For this reason, combined
PDE3-PDE4 inhibitors such as Zardaverine have been
w xconsidered as possible bronchodilating drugs 18–22 .
We report here for the first time that a PDE4 in
cultured VSMC is rapidly activated by forskolin and
by PKA in cell homogenates, findings consistentc
with the hypothesis that activation in intact VSMC is
mediated by PKA-catalyzed phosphorylation.
2. Material and methods
2.1. Cell culture
VSMC from bovine aorta were cultured as de-
w xscribed by Crossman et al. 23 with minor modifica-
tions. Bovine aortas, obtained from a local slaughter-
house, were opened longitudinally, the internal sur-
faces were scraped with a scalpel to remove endothe-
 .lium, and explants ;2=2 mm , cut from the me-
dia, were placed in 25-cm2 tissue culture flasks,
 .usually ;10rflask , where they were allowed to
adhere for 3 h in Dulbecco’s modified Eagle medium
 .DMEM, Gibco supplemented with 10% fetal calf
serum, penicillin 100 IUrml and streptomycin 100
 .mgrml. Additional DMEM 5 ml was added and the
flasks were incubated at 378C in air with 5% CO2
and 100% humidity. Media were changed every 3–4
days; confluent cultures were obtained in about 2
weeks. Cells were harvested after incubation with
  .trypsin 0.25% trypsin, 1 mM EDTA Gibco , 50
2 .mlrcm , 10 min, 378C and distributed to 6-well cell
 .culture plates Costar , where cultures became con-
fluent in ;1 week.
 .For immunostaining of a-smooth muscle SM
actin, cells were grown in plastic chambers on slides
 .Nunc Chamber Slides, 4 wells . Cells were fixed
with ethanolr5% acetic acid at y208C for 20 min,
incubated with monoclonal antibodies against a-SM
 .actin Sigma Diagnostics , stained with peroxidase-
coupled secondary antibody and 3-amino-9-ethyl car-
 .bazole AEC chromogen and mounted in glycerol-
gelatin. In experiments reported here, cells, usually
confluent cultures, were immunopositive for a-SM
actin.
2.2. Preparation of supernatants from VSMC incu-
bated with forskolin
Confluent cultures were washed twice with DMEM
without serum, then incubated at 378C in DMEM
with indicated additions and 5% CO . Experiments2
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were usually performed in the presence of 100 mM
N v-nitro-L-arginine to inhibit any NOS that might be
induced.
Cells were harvested by scraping with a plastic
 .cellscraper Costar in 200–1000 ml of homogeniz-
ing buffer 50 mM Tris, pH 7.3, 1 mM EDTA, 5 mM
MgCl , 0.03% of the non-ionic detergent C E ,2 13 12
 . 10% glycerol, antipain 20 mgrml , leupeptin 10
.  .mgrml , pepstatin 10 mgrml , 50 mM phenyl phos-
.phate, 25 mM NaF and transferred to a cooled glass
 . homogenizer Konte . They were homogenized 10
. strokes and the homogenate was centrifuged 48C,
.12 000=g, 15 min to obtain the supernatants used
for experiments reported here.
2.3. PDE assay
PDE activity was assayed by a modification of a
w xpublished 24 procedure. Samples of supernatants
were incubated for 8 min at 308C in a total volume of
300 ml of 50 mM Hepes, pH 7.5, 0.1 mM EDTA, 8.3
3 mM MgCl , 0.5 mM H-cAMP NEN, ;2502
.cpmrpmol cAMP . Hydrolysis of substrate did not
exceed 20% and PDE activity was proportional to
enzyme concentration. PDE4 activity was calculated
as activity in absence of rolipram minus activity in
 .presence of 10 mM rolipram Schering . Activity is
reported as pmol cAMP hydrolyzedrmin per mg
 .supernatant protein mean of duplicate assays . The
proportion of PDE4 was estimated at 40–60% of
total PDE activity.
Protein was assayed by the method of Bradford
w x  .25 with albumin 2–10 mg as standard.
2.4. PKA assay
PKA activity was determined according to the
w xmethod of Egan et al 26 . Samples were incubated
for 10 min at 308C in a total volume of 60 ml of 20
mM MOPS, pH 7.0, 16 mM Mg-acetate, 125 mM
32  6ATP, g- P-ATP ;5 Cirmmol, ;10 cpmrsam-
.ple , 4 mM DTE, 60 mM Kemptide, in the presence
or absence of 16 mM cAMP which induces maximal
.activation of PKA . The amount of Kemptide phos-
phorylated in the presence or absence of cAMP was
determined by scintillation counting and the ratio was
calculated. The degree of activation of PKA was
expressed as this ratio.
2.5. Acti˝ation of PDE4 by PKA in ˝itroc
VSMC supernatants 200 ml in homogenisation
.buffer, ;40–80 pmolrmin total PDE activity were
incubated at 308C for 15 min with bovine PKA c
 .Sigma P2645 , 100 Urml, in a final volume of 900
ml containing 50 mM Hepes, pH 7.5, 40 mM ATP, 5
mM MgCl , 5 mM EDTA, 150 mM EGTA, 1 mM2
 .dithiothreitol, 0.5 mM cAMP, antipain 20 mgrml ,
 .  .leupeptin 10 mgrml and pepstatin 10 mgrml .
2.6. Sephacryl S-200 and MonoQ chromatography
VSMC supernatant 600 ml, 60–120 pmolrmin
. PDE4 activity was applied to a column 0.9=45
.  .cm of Sephacryl S-200 Pharmacia equilibrated and
eluted with 50 mM Tris, pH 7.4, 1 mM EDTA, 5 mM
MgCl , 0.03% C E , 10% glycerol and 100 mM2 13 12
NaCl at a flow rate of 3 mlrh. 1-ml fractions were
collected for assay of PDE activity.
VSMC supernatant 600 ml, 60–120 pmolrmin
.PDE4 activity was diluted to 2 ml in 50 mM Tris,
pH 7.4, 1 mM EDTA, 5 mM MgCl , 0.03% C E ,2 13 12
 . 10% glycerol, antipain 20 mgrml , leupeptin 10
.  .mgrml , pepstatin 10 mgrml , 50 mM phenyl phos-
 .phate, 25 mM NaF. A sample 2 ml was applied to a
 .MonoQ HR5r5 column Pharmacia previously equi-
librated in dilution buffer and eluted with a linear
 .gradient of 0–500 mM NaCl 1 mlrmin, 40 ml .
1-ml fractions were collected for assay of PDE activ-
ity.
3. Results
3.1. Effects of forskolin on PKA and PDE4 acti˝ity in
VSMC
Stimulation of VSMC with forskolin resulted in a
concentration-dependent increase in cAMP, estimated
 .by an increase in the PKA ratio Fig. 1 , and in PDE4
 .activity Fig. 2 . Stimulation of the PKA ratio was
 .maximal at 60 mM forskolin Fig. 1 .
Incubation of VSMC with 100 mM forskolin re-
sulted in a rapid increase in PDE4 activity in VSMC
 .supernatants Fig. 3 . PDE4 activity was increased
within the first few minutes of incubation with
forskolin, was close to maximal within 10–15 min
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Fig. 1. Concentration dependence of forskolin stimulated PKA
 6 .activity. VSMC 10 cells were incubated for 10 min with
different concentrations of forskolin. The cells were homogenized
and centrifuged, and PKA activity ratios in the supernatants were
assayed in duplicate as described in Section 2. Datapoints repre-
sent the mean"S.E.M. of data from 3 experiments.
and then remained elevated for at least ;60 min
 .Fig. 3 . Incubation of the cells with cycloheximide
 .100 mgrml for 60 min before addition of forskolin
did not significantly affect the increase in PDE4
activity measured after 10 min with forskolin, sug-
gesting that the increased activity was not related to
 .enzyme synthesis data not shown .
Forskolin-induced activation of PDE4 was main-
tained during Sephacryl S-200 chromatography of
VSMC supernatants from control and forskolin stim-
ulated VSMC. Total PDE4 activity in fractions from
Fig. 2. Effect of forskolin concentration on activation of PDE4 in
VSMC. VSMC were incubated in DMEM for 10 min with the
indicated concentration of forskolin and harvested, and specific
PDE4 activity was measured in VSMC supernatants. Results of
two experiments are presented as % of activity in unstimulated
cells at ts0.
Fig. 3. Time course of activation of PDE4 by forskolin in VSMC.
VSMC were incubated in DMEM with 100 mM forskolin for
indicated times, harvested and specific PDE4 activity was mea-
sured in VSMC supernatants as described. Data from three
experiments are presented as % of activity of unstimulated cells.
forskolin-stimulated cells was 3.7-fold higher than in
corresponding fractions from control cells Fig. 4,
.lower insert . After MonoQ chromatography, PDE4
Fig. 4. Sephacryl S-200 chromatography of supernatants from
control and forskolin stimulated cells. VSMC were incubated in
DMEM for 10 min without or with 100 mM forskolin before
homogenization. Supernatants were subjected to gel filtration on
 .Sephacryl S-200. Total PDE activity top and PDE4 activity
 .bottom was measured in indicated fractions.
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Fig. 5. Activation of PDE4 by PKA in vitro. Duplicate samplesc
from pooled VSMC supernatants were incubated for 15 min at
308C in presence of ATP without or with PKA and PKI asc
indicated before measurement of PDE4 activity.
activity in samples from stimulated cells was 1.3–1.7
times that in samples from control cells data not
.shown . Taken together, these results suggest that a
PKA-dependent phosphorylation is most likely res-
ponsible for forskolin-induced activation of PDE4 in
VSMC.
3.2. In ˝itro acti˝ation of PDE4 by PKAc
Incubation of VSMC supernatant with PKA andc
ATP resulted in a ;5-fold rise in PDE4 activity
 .  .Fig. 5 , with a time-course Fig. 6 similar to that
observed in intact VSMC incubated with forskolin
 .Fig. 3 . Activation was completely blocked by pro-
 .  .tein kinase inhibitor PKI Fig. 5 .
During incubation of homogenates from
Fig. 6. Time course of activation of PDE4 by PKA in vitro.c
Samples from pooled VSMC supernatants were incubated at
308C with PKA and ATP and PDE4 activity measured atc
indicated times.
Fig. 7. Reversal of forskolin activation of PDE4 and reactivation
with PKA . Duplicate VSMC cultures were incubated for 10 minc
 .  .with I or without ^ 100 mM forskolin. The cells were
homogenized and PDE4 activity measured in supernatant frac-
 .tions ts0 . Samples of supernatants were incubated at room
temperature for 120 min and some were then further incubated at
308C for 15 min with PKA under activation conditions beforec
assay of PDE4 activity.
forskolin-stimulated VSMC at room temperature for
2 h, PDE4 activity decreased almost to control values
 .Fig. 7 . Incubation with PKA and ATP for 15 minc
induced a 5-fold increase in of PDE4 activity, indicat-
ing that inactivation was not due to protein degrada-
tion or other irreversible processes. The reduction in
activity was not significantly increased by addition of
 .protein phosphatase 2A PP2A to the sample. The
 .PP2A-specific inhibitors okadaic acid 0.25 mM and
 .microcystin LR 10 mM only slightly reduced the
 .inactivation data not shown , suggesting that PDE4
 .was inactivated by endogenous phosphatase s other
than PP2A.
4. Discussion
It has recently been reported that a PDE4 isoen-
zyme in thyroid-derived FRTL-5 cells incubated with
 .thyroid-stimulating hormone TSH was rapidly acti-
w xvated by PKA-dependent phosphorylation 12 . Hor-
mones that elevate cAMP are also known to increase
PDE4 mRNA and enzyme activity by increasing gene
transcription, e.g., in Sertoli cells and in FRTL-5
cells in response to follicle-stimulating hormone
 . w x w xFSH 27 and TSH 12 , respectively. Similarly,
dibutyryl-cAMP and forskolin increased PDE4
w xmRNA in skeletal muscle myoblasts 28 .
Here we present for the first time evidence for
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rapid and reversible PKA-dependent activation of a
PDE4 in VSMC. As is the case in Sertoli cells and
FRTL5 cells, a direct phosphorylation of VSMC
PDE4 is most likely, although it can not be com-
pletely ruled out that PKA mediates its effect through
 .other kinase s . Activation, which occurred within
less than 15 min in response to the adenylyl cyclase
activator forskolin, was not inhibited by cyclohex-
imide, suggesting that it was not due to synthesis of
new enzyme. It was also preserved during partial
purification, suggesting that it reflected a stable, co-
valent modification. In vivo, forskolin induced activa-
tion of PKA, and, in vitro, incubation with PKA c
activated PDE4 with the same time course as that in
intact cells incubated with forskolin, supporting the
idea that rapid activation in VSMC is in fact medi-
ated by PKA.
The functional significance of the acute regulation
of PDE4 by PKA in VSMC is not understood. The
increase in PDE activity in response to increased
cAMP could play a role in heterologous desensitiza-
tion to hormone stimulation of adenylyl cyclase. Also,
it has been shown in a cell-free system that, under
conditions of rapid cAMP turnover, half-maximal
PKA activation occured at a much lower cAMP
w xconcentration than required at slow turnover 29 . It is
possible that such a mechanism could be operative in
stimulated VSMC, where in the presence of increased
PDE activity and perhaps increased turnover of
.cAMP PKA could be activated by relatively small
increases in cAMP.
Variations in cAMP and consequently in PKA
activity are known to influence both cell proliferation
and contraction in VSMC. On the one hand, cAMP is
involved in regulation of proliferation of certain cells,
and inhibition of both PDE3 and PDE4 antagonizes
w x w xproliferation of cultured rat 30 and porcine 31
w x w xaortic smooth muscle cells, human 32 and rat 33
w xT-lymphocytes, and rat mesangial cells 34 . Salbuta-
mol, a b-receptor agonist, blocks proliferation of
w xcultured human airway smooth muscle cells 35 . On
the other hand, in VSM, hormones and agents which
increase cAMP also lower calcium probably at least
in part by cAMP-mediated stimulation of reuptake
.into the sarcoplasmatic reticulum and promote relax-
w xation 14 . Activation of PDEs by cAMP-elevating
agents might modulate cAMP-mediated relaxation or
reduce the duration of the relaxation.
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